News
ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback